Medical News Home

Argos Therapeutics today announced the publication of a paper in the October 15th issue of the Journal of Immunonology demonstrating that the Company’s proprietary RNA-electroporated dendritic cells generate high-avidity cytotoxic T cells (CTL) in vitro that are able to destroy cells expressing their target antigens.

Researchers have developed a method of assessing the quality of phase I clinical trial abstracts submitted to two different oncology conferences: EORTC-NCI-AACR (ENA) [1] and American Society of Clinical Oncology (ASCO).

Pharmaceutical companies across the industry have significantly cut outlays to outsourcing as a percentage of clinical development budgets, according to “Streamlining Clinical Trials,” a new study by pharmaceutical business intelligence leader Cutting Edge Information.

A new speaking book, designed to explain the rights and responsibilities of people entering into clinical trials, has been launched for use in Africa.

The Multiple Myeloma Research Consortium (MMRC) today announced the initiation of a three-drug combination study of elotuzumab (also known as HuLuc63), a humanized anti-CS1 monoclonal IgG1 antibody administered intravenously, in combination with REVLIMID® (lenalidomide), and dexamethasone for the treatment of multiple myeloma in patients who are experiencing a relapse.

A new international study found that Merck’s pain killer Vioxx (rofecoxib), which the drug company voluntarily withdrew from the market in 2004, found that a near two-fold increased risk of heart, stroke and death persisted for up to one year after stopping use.

Researchers from Syracuse Preventive Medicine, NY, USA discuss a new drug called ranolazine that has been deemed a safe and effective treatment for chronic stable angina. Drs Stephen Nash and David Nash discuss this new treatment option in a New Drug Class paper published in The Lancet.

Ranolazine, a new treatment for chronic, stable angina, is discussed as a safe and effective option for patients in a New Drug Class paper released on October 10, 2008 in The Lancet. Chronic stable angina is a prolonged chest pain which is often linked to heart disease. It is often present when the patient is exercising.

The prospect of receiving innovative treatment proved to be the number one patient recruitment incentive, according to “Streamlining Clinical Trials,” a new study by pharmaceutical business intelligence leader Cutting Edge Information.

SNM, an international scientific and medical association dedicated to advancing molecular imaging and therapy, today announced the creation of the Molecular Imaging Clinical Trials Network. The network is a response to the need for streamlined processes to utilize imaging biomarkers in clinical research and clinical practice.